Previous Close | 160.74 |
Open | 160.08 |
Bid | 163.00 x 100 |
Ask | 165.00 x 100 |
Day's Range | 159.81 - 166.00 |
52 Week Range | 123.73 - 192.15 |
Volume | 4,194,542 |
Avg. Volume | 1,493,636 |
Market Cap | 49.129B |
Beta | 1.47 |
PE Ratio (TTM) | 11.71 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.05 (0.69%) |
Ex-Dividend Date | 2018-03-08 |
1y Target Est | N/A |
Apr.20 -- Takeda Pharmaceutical Co. plans to sweeten its offer for drugmaker Shire Plc to more than $60 billion after a prior bid was rejected, according to people with knowledge of the matter. Les Funtleyder, portfolio manager at E Squared Capital Management, speaks with Bloomberg's Vonnie Quinn on "Bloomberg Markets."
CNBC’s David Faber reports that Japanese drug company Takeda is increasing its proposal for Shire.
Japan’s Takeda said it had made a sweetened proposal to buy Shire after its three previous bids for the rival drugmaker that has drawn broader interest across the sector were rejected.
Botox maker Allergan said it will no longer consider bidding for Shire.
The brouhaha surrounding Shire continued Friday after Takeda made a fourth bid to buy the drugmaker, sweetening the pot from an earlier bid that valued the company around $61 billion.
TOKYO/LONDON (Reuters) - Japan's Takeda Pharmaceutical nudged up its offer for Shire to 44.3 billion pounds ($62 billion) on Friday to try to persuade the rare-disease drugs specialist into talks after it rejected three previous proposals. Japan's biggest drugmaker increased its potential cash and shares bid to 47 pounds a share, up 1 percent from its previous proposal of 46.50 pounds. It also lifted the cash component by 3.25 pounds to 21 pounds a share, a shift that analysts said was needed to appeal to Shire's shareholders.
TOKYO/LONDON (Reuters) - Japan's Takeda Pharmaceutical nudged up its offer for Shire (SHP.L) to 44.3 billion pounds on Friday to try to persuade the rare-disease drugs specialist into talks after it rejected three previous proposals. Japan's biggest drugmaker increased its potential cash and shares bid to 47 pounds a share, up 1 percent from its previous proposal of 46.50 pounds. It also lifted the cash component by 3.25 pounds to 21 pounds a share, a shift that analysts said was needed to appeal to Shire's shareholders.
Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.
U.K. stocks on Friday advance for a fourth straight day, closing at the highest level in about 11 weeks, partly prompted by a drop in the pound after Bank of England Gov. Mark Carney suggested that an ...
Takeda Pharmaceutical Co. plans to sweeten its offer for drugmaker Shire Plc to more than $60 billion after a prior bid was rejected, according to people with knowledge of the matter. Les Funtleyder, portfolio ...
Takeda raises offer for Shire for a fourth time to £42.8bn
Japan's Takeda Pharmaceutical Co Ltd is considering raising its cash-and-stock bid for London-listed drug maker Shire Plc to approximately 47 pounds per share or more, people familiar with the matter said ...
(Reuters) - Japan's Takeda Pharmaceutical Co Ltd is considering raising its cash-and-stock bid for London-listed drug maker Shire Plc (SHP.L) to approximately 47 pounds per share or more, people familiar ...
Takeda Pharmaceutical Co. sweetened its offer for drugmaker Shire Plc to more than $60 billion after three prior bids were rejected, wooing investors in the U.S. company with a higher cash component.
Shares in Shire were on the slide on Friday as the chatter on the trading floors was that a takeover of the pharmaceuticals giant is now doomed. Shire said yesterday afternoon that it had rejected three offers from Takeda of Japan, and that triggered the revelation that US firm Allergan had also taken a look but decided against making an offer. Shire says it wants to keep talking but traders believe enough is enough, and Takeda would struggle to put together a bigger offer.
Allergan had made it known that it had contemplated an offer but then decided against it, which sent Shire’s share price down at 3,823 pence from yesterday’s close at 3,831 pence. Takeda shares fell by 4.67 per cent. Shire on Friday confirmed that Allergan had backed away.
Shire has said it is “considering” its response to an improved offer from Takeda, after the Japanese pharmaceutical group sweetened its approach to the Dublin-based rare diseases company by roughly £455m on Friday.
Three years ago, Christophe Weber made waves in Japan when 237-year-old Japanese drugmaker Takeda Pharmaceutical Co. named him its first foreign chief. These days, he’s in the hot seat for his controversial ...
Drugmaker Shire rebuffed a takeover bid from rival Takeda Pharmaceutical, then Allergan took a look.
Shire has rejected Takeda’s three offers to buy it, and there may not be much more wiggle room to sweeten the bid.
Japanese pharmaceutical group Takeda sweetened its offer for rival Shire by roughly £455m on Friday and shifted a significant portion of its proposal from stock to cash in a bid to win over the board of ...
Takeda's made three offers to acquire Shire in the past month. Now a new bidder is emerging for the U.K. biopharma.
- Brunswick founder Alan Parker resigned as chair of Save the Children after current and former employees criticised his handling of sexual harassment at the charity. - Shire Plc rejected a 42.4 billion pound takeover offer from Japanese rival Takeda Pharmaceutical Co Ltd and Botox-maker Allergan Plc disclosed it had considered a run at the company but said it "does not intend to make an offer for Shire".
- Brunswick founder Alan Parker resigned as chair of Save the Children after current and former employees criticised his handling of sexual harassment at the charity. - Shire Plc rejected a 42.4 billion pound takeover offer from Japanese rival Takeda Pharmaceutical Co Ltd and Botox-maker Allergan Plc disclosed it had considered a run at the company but said it "does not intend to make an offer for Shire".
The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times Ultra Electronics Holdings Plc has ...